Hongye Zhao

Hongye Zhao currently serves as BD Director at ArriVent Biopharma since January 2022, bringing extensive experience in business development within the biopharmaceutical industry. Previously, Hongye held the position of Head of BD at 纽福斯生物 for a brief period in 2021, and served as Director of Business and Development at IASO BioTherapeutics from March 2017 to July 2021, where responsibilities included developing license-in/out strategies and facilitating scientific evaluations across various teams. Prior roles include Investment Associate at NEW VISION VENTURES LTD, focusing on healthcare deal sourcing and evaluation, and Researcher at the University of Rochester Medical Center. Hongye began a career in quality control at Beijing Tiantan Biological Products Co., Ltd. Hongye holds an MBA in Marketing from the University of Rochester - Simon Business School and a Master of Science in Biotechnology from Adelphi University.